Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Deaths Stop Infinity Pharma's Phase III HSP90 Trial In Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Infinity Pharmaceuticals' decision to pull the plug on the registrational Phase III trial with heat shock protein 90 inhibitor IPI-504 - the only product not part of the broad-ranging deal with affiliated specialty pharmas Purdue and Mundipharma - put a chill into investors April 15

You may also be interested in...



Infinity Regains Rights To Its Lead Program

Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.

With Innovative Purdue Deal, Infinity Finds Shelter From The Storm

In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.

Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone

In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel